Asset
DUPILUMAB
Regeneron Pharmaceuticals Inc. Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (40)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT07112378 | phase3 | recruiting | 2025-11-10 | 2028-06-19 | Regeneron Pharmaceuticals | A Study of Dupilumab in Small Children With an Allergic Condition of the Esophagus (Food Pipe): Eosinophilic Esophagitis |
| NCT02755649 | phase3 | completed | 2016-01-31 | 2017-01-04 | Regeneron Pharmaceuticals | A Study to Assess the Efficacy and Safety of Dupilumab in Participants With Severe Atopic Dermatitis (AD) That Are Not Controlled With Oral Cyclosporine A (CSA) or for Those Who Cannot Take Oral CSA Because it is Not Medically Advisable |
| NCT02395133 | phase3 | completed | 2015-03-25 | 2016-07-01 | Regeneron Pharmaceuticals | A Study to Confirm the Efficacy and Safety of Different Dupilumab Dose Regimens in Adults With Atopic Dermatitis (AD) |
| NCT02407756 | phase2 | completed | 2015-03-31 | 2016-03-31 | Regeneron Pharmaceuticals | A Study to Determine the Safety and Tolerability of Dupilumab (REGN668/SAR231893) in Patients Aged ≥6 to <18 Years With Atopic Dermatitis (Eczema) |
| NCT04203797 | phase4 | completed | 2020-07-16 | 2023-07-15 | Regeneron Pharmaceuticals | A Study to Evaluate the Effect of Dupilumab on Exercise Capacity in Adult Patients With Asthma |
FDA applications (1)
| Application | Type | Applicant |
|---|---|---|
| BLA 761055 | BLA | Regeneron Pharmaceuticals, Inc. |
Marketed products (6)
- DUPIXENT
- Dupixent
- Dupixent
- Dupixent
- Dupixent
- Dupixent